Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 6, 2010, Pages 769-776

  Chang, Rae Sung ^a,b   Kim, Jiyeon ^a   Lee, Han Young ^a   Han, Su Eun ^a   Na, Jinhee ^c   Kim, Kwangmeyung ^c   Kwon, Ick Chan ^c   Kim, Young Bong ^d   Oh, Yu Kyoung ^b  

^a Korea University   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Konkuk University   (South Korea)

Author keywords

Cardiolipin liposomes; Dose limiting toxicity; Intraperitoneal chemotherapy; Mitoxanthrone; Prolonged retention

Indexed keywords

CARDIOLIPIN LIPOSOMES; DOSE LIMITING TOXICITY; INTRAPERITONEAL; MITOXANTHRONE; PROLONGED RETENTION;

BINDING ENERGY; CHEMOTHERAPY; DRUG DOSAGE; DYES; ELECTROSTATICS; ENCAPSULATION; LIPOSOMES; OPTIMIZATION; TOXICITY; TUMORS;

PHOSPHOLIPIDS;

CARDIOLIPIN; LIPOSOME; MITOXANTRONE; MITOXANTRONE LIPOSOME CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CARCINOMATOSIS; CARDIOTOXICITY; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; DRUG STRUCTURE; ENCAPSULATION; FEMALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM TUMOR; STATIC ELECTRICITY; SURFACE PROPERTY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOLIPINS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MICE; MITOXANTRONE;

EID: 78649845506     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.05.003     Document Type: Article

References (20)

1. Cotte E., Passot G., Mohamed F., Vaudoyer D., Gilly F.N., Glehen O. Management of peritoneal carcinomatosis from colorectal cancer: Current state of practice. Cancer J 2009, 15:243-248.
2. Muggia F.M. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment. Semin Oncol 2006, 33:S18-S24.
3. Van der Speeten K., Stuart O.A., Sugarbaker P.H. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 2009, 15:216-224.
4. Chua T.C., Yan T.D., Saxena A., Morris D.L. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg 2009, 249:900-907.
5. Markman M. Antineoplastic agents in the management of ovarian cancer: Current status and emerging therapeutic strategies. Trends Pharmacol Sci 2008, 29:515-519.
6. Schmidt U., Dahlke M.H., Klempnauer J., Schlitt H.J., Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005, 31:53-58.
7. Lim S.J., Cormier J.N., Feig B.W., Mansfield P.F., Benjamin R.S., Griffin J.R., et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol 2007, 14:2309-2318.
8. Keese M., Gasimova L., Schwenke K., Yagublu V., Shang E., Faissner R., et al. Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. Int J Cancer 2009, 124:2701-2708.
9. Lu B., Xiong S.B., Yang H., Yin X.D., Chao R.B. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006, 28:86-95.
10. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv 2007, 4:297-305.
11. Madhusudan S., Tamir A., Bates N., Flanagan E., Gore M.E., Barton D.P., et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004, 10:2986-2996.
12. Oh Y.K., Park T.G. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009, 61:850-862.
13. Han S.E., Kang H., Shim G.Y., Suh M.S., Kim S.J., Kim J.S., et al. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm 2008, 353:260-269.
14. Bertschinger M., Backliwal G., Schertenleib A., Jordan M., Hacker D.L., Wurm F.M. Disassembly of polyethylenimine-DNA particles in vitro: Implications for polyethylenimine-mediated DNA delivery. J Control Release 2006, 116:96-104.
15. Layman J.M., Ramirez S.M., Green M.D., Long T.E. Influence of polycation molecular weight on poly(2-dimethylaminoethyl methacrylate)-mediated DNA delivery in vitro. Biomacromolecules 2009, 10:1244-1252.
16. Srinivasachari S., Liu Y., Prevette L.E., Reineke T.M. Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy. Biomaterials 2007, 28:2885-2898.
17. Li C., Cui J., Wang C., Li Y., Zhang H., Wang J., et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 2008, 70:657-665.
18. Zucker D., Marcus D., Barenholz Y., Goldblum A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J Control Release 2009, 139:73-80.
19. 2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation. Int J Pharm 2009, 368:24-30.
20. Mauritz R., Peters G.J., Kathmann I., Teshale H., Noordhuis P., Comijn E.M., et al. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. Cancer Chemother Pharmacol 2008, 62:937-948.